![]() Thus, cross-linked HA:HPβCD inserts appear as a suitable platform for peptide drug release to the ocular surface.Ĭross-linked hydrogel Cyclodextrin Cyclosporine Ocular insert Release test set-up Sodium hyaluronan.Ĭopyright © 2018 Elsevier Ltd. These later inserts also facilitated cyclosporine accumulation into sclera (5.6-32.7 μg drug/g sclera). Conversely, differences among formulations were evidenced when the inserts were immersed in plenty volume of fluid inserts with low content in HPβCD released the drug faster. Release tests carried out under continuous flow of simulated lacrimal fluid revealed a controlled release of cyclosporine during the first 1 h. ![]() Cyclosporine-loaded inserts (∼0.5% w/w drug content) appeared translucent. The inserts (300 μm thickness) showed porous surfaces, high swelling ratios (∼10), and good cytocompatibility with fibroblasts and chorioallantoic membrane (HET-CAM test). BroadPharm provides monofunctional or heterobifunctional hydroxyl PEGs (PEG Alcohols) with various active groups, including Alkyne, carboxylic acid, NHS ester, PFP ester, Tosyl, Amine, Azide, Bromide, etc. Four different formulations, cross-linked with poly(ethylene glycol) diglycidyl ether, were studied to elucidate the role of the HA:HPβCD proportion on the physical characteristics and drug release patterns. Electronic address: work aimed to develop cyclosporine ocular inserts combining sodium hyaluronate (HA) and hydroxypropyl-β-cyclodextrin (HPβCD). 4 Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, R+DPharma Group (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain.Electronic address: 1 Food and Drug Department, University of Parma, Italy Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, R+DPharma Group (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain. 3 Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, R+DPharma Group (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain.2 Food and Drug Department, University of Parma, Italy.1 Food and Drug Department, University of Parma, Italy Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, R+DPharma Group (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain.
0 Comments
Leave a Reply. |